AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction

AIM ImmunoTech Inc (NYSE: AIM) has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD).
The trial will evaluate the efficacy and safety of Ampligen in patients experiencing PCCD.
Eighty subjects will be randomized 1:1 to receive twice-weekly infusions of Ampligen or placebo for 12 weeks.
Related Content: AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study.
Price Action: AIM stock is down 0.99% at $2.01 during the market session on the last check Wednesday.